IL207530A - Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug - Google Patents

Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug

Info

Publication number
IL207530A
IL207530A IL207530A IL20753010A IL207530A IL 207530 A IL207530 A IL 207530A IL 207530 A IL207530 A IL 207530A IL 20753010 A IL20753010 A IL 20753010A IL 207530 A IL207530 A IL 207530A
Authority
IL
Israel
Prior art keywords
substituted
group
triazolyl
nitrogen
moiety
Prior art date
Application number
IL207530A
Other languages
English (en)
Hebrew (he)
Other versions
IL207530A0 (en
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL207530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IL207530A0 publication Critical patent/IL207530A0/en
Publication of IL207530A publication Critical patent/IL207530A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL207530A 2008-02-21 2010-08-10 Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug IL207530A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21
PCT/US2009/034447 WO2009105500A1 (en) 2008-02-21 2009-02-19 Compounds that are erk inhibitors

Publications (2)

Publication Number Publication Date
IL207530A0 IL207530A0 (en) 2010-12-30
IL207530A true IL207530A (en) 2014-08-31

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207530A IL207530A (en) 2008-02-21 2010-08-10 Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug

Country Status (23)

Country Link
US (1) US8716483B2 (https=)
EP (1) EP2260031B1 (https=)
JP (1) JP5276676B2 (https=)
KR (1) KR20100117123A (https=)
CN (1) CN102015693B (https=)
AR (1) AR070460A1 (https=)
AU (1) AU2009215534B8 (https=)
BR (1) BRPI0908120A8 (https=)
CA (1) CA2714479A1 (https=)
CL (1) CL2009000394A1 (https=)
CO (1) CO6300939A2 (https=)
EC (1) ECSP10010415A (https=)
ES (1) ES2556353T3 (https=)
IL (1) IL207530A (https=)
MX (1) MX2010009268A (https=)
MY (1) MY152271A (https=)
NZ (1) NZ587504A (https=)
PE (1) PE20091491A1 (https=)
RU (1) RU2525389C2 (https=)
SG (1) SG188179A1 (https=)
TW (1) TWI398441B (https=)
WO (1) WO2009105500A1 (https=)
ZA (2) ZA201005909B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
US8586543B2 (en) 2008-08-19 2013-11-19 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
US8609675B2 (en) 2009-07-02 2013-12-17 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds as novel mTOR inhibitors
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
WO2011163330A1 (en) * 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
US9000209B2 (en) 2011-07-22 2015-04-07 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
BR112014030284B1 (pt) 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
WO2014052566A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX2015011438A (es) * 2013-03-13 2016-02-03 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina.
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
SG11201602572YA (en) 2013-10-03 2016-04-28 Kura Oncology Inc Inhibitors of erk and methods of use
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
CA2970717A1 (en) 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
BR112017012558A2 (pt) * 2014-12-19 2018-01-02 Merck Sharp & Dohme Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
MX379622B (es) * 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
UY38911A (es) 2019-10-09 2021-05-31 Bayer Ag Compuestos de heteroarilo-triazol como pesticidas, formulaciones, usos y métodos de uso de los mismos
KR102823105B1 (ko) 2019-12-06 2025-06-20 디3 바이오 (우씨) 컴퍼니, 리미티드 Erk 억제제로서 작용하는 스피로 화합물 및 이의 응용

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
KR20010111298A (ko) 2000-02-05 2001-12-17 버텍스 파마슈티칼스 인코포레이티드 Ｅｒｋ의 억제제로서 유용한 피라졸 조성물
CA2369502A1 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
EP1317453B1 (en) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60125980T2 (de) * 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
MXPA03009847A (es) 2001-04-27 2004-02-12 Vertex Pharma Inhibidores de cinasa derivados de pirazol.
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
DE60226154T2 (de) 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EP1423380B1 (en) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
JP4602667B2 (ja) 2001-10-23 2010-12-22 メルク セローノ ソシエテ アノニム アゾール誘導体および該アゾール誘導体を含有する医薬組成物
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
US7429609B2 (en) * 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
MY133311A (en) 2002-09-19 2007-11-30 Schering Corp Novel imidazopyridines as cyclin dependent kinase inhibitors
US7456190B2 (en) 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050107386A1 (en) * 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
WO2005063258A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7462612B2 (en) 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
EP1756082A1 (en) 2004-04-13 2007-02-28 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
AU2005245877B2 (en) 2004-05-14 2010-06-03 Vertex Pharmaceuticals, Incorporated Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
UA84930C2 (ru) 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
WO2006071644A1 (en) 2004-12-23 2006-07-06 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinases and uses therof
CN100377868C (zh) * 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
KR101417136B1 (ko) * 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US20090062355A1 (en) * 2006-04-20 2009-03-05 Takeda Pharmaceutical Company Limited Pharmaceutical Product
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
BRPI0713119A2 (pt) * 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
US7671832B2 (en) * 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MY148609A (en) 2007-06-05 2013-05-15 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
MX2009013213A (es) 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
CA2691417A1 (en) 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物

Also Published As

Publication number Publication date
ZA201005909B (en) 2014-03-26
TW200948799A (en) 2009-12-01
AU2009215534B8 (en) 2014-07-10
RU2010138635A (ru) 2012-03-27
EP2260031A1 (en) 2010-12-15
JP2011513225A (ja) 2011-04-28
AU2009215534A8 (en) 2014-07-10
AU2009215534A1 (en) 2009-08-27
ECSP10010415A (es) 2010-09-30
WO2009105500A1 (en) 2009-08-27
US20110189192A1 (en) 2011-08-04
CO6300939A2 (es) 2011-07-21
JP5276676B2 (ja) 2013-08-28
ES2556353T8 (es) 2017-10-13
MX2010009268A (es) 2010-09-14
NZ587504A (en) 2012-09-28
ES2556353T3 (es) 2016-01-15
KR20100117123A (ko) 2010-11-02
PE20091491A1 (es) 2009-09-25
AR070460A1 (es) 2010-04-07
CN102015693A (zh) 2011-04-13
MY152271A (en) 2014-09-15
RU2525389C2 (ru) 2014-08-10
CA2714479A1 (en) 2009-08-27
ZA201400396B (en) 2014-12-23
BRPI0908120A2 (https=) 2017-08-22
CL2009000394A1 (es) 2011-02-11
IL207530A0 (en) 2010-12-30
US8716483B2 (en) 2014-05-06
AU2009215534A2 (en) 2010-12-23
BRPI0908120A8 (pt) 2017-10-24
SG188179A1 (en) 2013-03-28
EP2260031B1 (en) 2015-10-07
AU2009215534B2 (en) 2014-06-26
CN102015693B (zh) 2014-10-29
TWI398441B (zh) 2013-06-11

Similar Documents

Publication Publication Date Title
IL207530A (en) Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug
AU2017232516B2 (en) Substituted inhibitors of menin-MLL and methods of use
KR102419524B1 (ko) 메닌-mll의 가교된 이환식 억제제 및 사용 방법
EP3205650B1 (en) Egfr inhibitor, and preparation and application thereof
RU2008128119A (ru) Новые соединения, действующие как ингибиторы erk
RU2009148867A (ru) Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2017533266A5 (https=)
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
CN114599361A (zh) Prmt5抑制剂的药物组合物
CN121800804A (zh) 用于抑制多发性内分泌抑癌蛋白与mll蛋白质的相互作用的方法及组合物
NZ596487A (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
IL311645B2 (en) 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
IL274936B2 (en) Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors
WO2008007123A3 (en) Pharmaceutical compounds
JP2008528467A5 (https=)
AU2019316858B2 (en) Smad3 inhibitors
Batran et al. Design, synthesis, and molecular modeling of quinoline‐based derivatives as anti‐breast cancer agents targeting EGFR/AKT signaling pathway
JP2010538091A5 (https=)
KR20150104089A (ko) 치환된 인돌-5-올 유도체와 그들의 치료적 용도
Xiao et al. Design, synthesis, and antitumor evaluation of quinoline‐imidazole derivatives
RU2017139771A (ru) Бициклические соединения
CA3136492A1 (en) Heterocyclic compounds and uses thereof
JPWO2020032105A5 (https=)
JP2019537598A (ja) ２−多置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed